Lower Respiratory Tract Infection (LRTI) Clinical Trial
Official title:
Procalcitonin Antibiotic Consensus Trial (ProACT)
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory Tract Infection (LRTI).
There is a need for improved decision-making for antibiotic prescription in acute suspected
infection. Infections, particularly in the early stages, can have protean manifestations,
often do not manifest with "classic" signs, and clinically overlap with non-infectious
conditions. However, the imperative to quickly give antibiotics for bacterial infection has
led to antibiotic overuse and resistance.
Strategies that combine novel diagnostics with therapeutics have improved decision-making in
oncology, cardiology, and other fields. These strategies aim to identify those patients most
likely to be helped or harmed by the therapeutic intervention and allow more individualized
care. This approach takes diagnostics to the next level, by demanding a test not only measure
well, but also that clinical care be improved by tying the test to a treatment strategy.
Procalcitonin, a novel biomarker of bacterial infection, may help physicians make more
appropriate antibiotic decisions. Lower respiratory tract infection (LRTI) is an ideal trial
population. LRTI accounts for a large proportion of antibiotic prescription, and exemplifies
the imprecise clinical phenotype of infection.However, key questions of generalizability and
safety preclude widespread application.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00353951 -
An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care
|
N/A |